The mu opioid receptor displays basal signaling activity, which appears to be enhanced by exposure to opioid agonists. This study assesses the in vivo pharmacology of the putative "neutral" antagonist 6ß-naltrexol in comparison to other ligands with varying efficacy, such as naloxone, an inverse agonist in the opioid dependent state. ICR mice were used to generate full antagonist dose-response curves for naloxone, naltrexone, nalbuphine and 6ß-naltrexol in blocking acute antinociceptive effects of morphine and precipitating opioid withdrawal in models of physical dependence. 6ß-Naltrexol was roughly equipotent to naloxone and between 4.5 and 10-fold less potent than naltrexone in blocking morphine-induced antinociception and locomotor-activity, showing that 6ß-naltrexol enters the central nervous system. In contrast to naloxone and naltrexone, 6ß-naltrexol precipitated only minimal withdrawal at high doses in an acute dependence model and was ~77-fold and 30-fold less potent than naltrexone and naloxone, respectively, in precipitating withdrawal in a chronic dependence model. 6ß-Naltrexol reduced the inverse agonist effects of naloxone in vitro and in vivo, as expected for a neutral antagonist.
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2004; 2001). In contrast, the mu opioid receptor antagonist CTAP acts as a neutral antagonist in vitro, while producing a less severe withdrawal than naloxone or naltrexone in opioid dependent animals (Maldonado et al., 1992a; Wang et al., 1994; Bilsky et al., 1996; Cruz et al., 1996; Liu and Prather, 2001; Sterious and Walker, 2003) .
An in vitro screen of several naloxone and naltrexone derivatives identified ligands with high affinity for mu and delta opioid receptors and less inverse agonist activity than the parent compounds in opioid dependent cell lines (Wang et al., 2001) . We recently reported an initial in vivo characterization of these proposed neutral antagonists, including their ability to precipitate withdrawal in opioid dependent mice, leading to the identification of 6ß-naltrexol as a viable lead compound ( Figure 1 ) (Wang et al., 2004) . In this paper, we present a comprehensive study of the in vivo pharmacology of naloxone, naltrexone and 6ß-naltrexol ( Figure 1 ). We have also included the partial opioid agonist nalbuphine for comparison purposes. The results further support the hypothesis that basal signaling at the mu opioid receptor occurs in vivo and that compounds that differ in terms of intrinsic efficacy produce quantifiable differences in the severity of precipitated withdrawal. Our results also indicate that regulation of basal signaling and/or ligand efficacy is differentially regulated in the different mouse brain regions we have examined.
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Locomotor Studies for Determining Antagonist Potencies. Locomotor-activity was measured using an activity monitoring system (Coulbourn Instruments) and Truscan software. Each of the eight chambers consists of 10"W x 10"L x 16"H arena surrounded by Plexiglas walls. The floor consists of a removable plastic drop pan that is cleaned between sessions. A sensor ring surrounds the arena on the bottom outside edges of the four sides of the chamber and contains 16 infrared beams that transect both the length and the width of the chambers on all four sides (beam spacing = 0.6 inches, resolution of 32 x 32 squares). Measurement of the animals' position is determined every 100 milliseconds and the software calculates a number of parameters related to aspects of locomotor-activity. The total distance traveled by each mouse was used as the primary measure of activity, with the data summed into 5-minute intervals (bins). Mice were habituated to the chamber for 30 minutes and then administered two injections within a one minute time span. The first injection was given i.p. and consisted of vehicle or various doses of the test compounds. The second injection was given s.c. and was either vehicle or a fixed dose of morphine (30 mg/kg). This dose of morphine was previously determined to produce robust stimulation of forward locomotion with stereotypic circling around the perimeter of the arena and Straub tail. Mice were immediately placed back into the chambers and monitored for an additional 90 minutes. Sessions were divided into 24 5-minute bins with the distance traveled calculated for each mouse. The time period from 20 to 50 minutes after the injections was chosen for analysis as this was a time when morphine was reaching its peak effect and when all antagonists were producing maximal blockade. For calculation of ID 50 values, data were expressed as a percent of controls. The control morphine effect was calculated by taking the mean distance traveled by the morphine control and subtracting the mean distance traveled by the vehicle control. The data for each individual mouse receiving a dose of the test compound This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 16, 2005 as DOI: 10.1124 at ASPET Journals on November 13, 2017 jpet.aspetjournals.org Downloaded from was then expressed as a percentage of this control. ID 50 values (and 95% confidence interval) were calculated using linear regression (FlashCalc software).
Locomotor Studies for Determining Onset of Antagonist Blockade. To estimate the functional pharmacokinetic parameters of onset of antagonist effect we used a modified version of the locomotor assay described above. The total distance traveled was summed into one-minute intervals to give better temporal resolution of the drug effects. Following a 30-minute habituation, mice received an injection of morphine sulfate (30 mg/kg, s.c.) and were immediately placed back into the chambers for an additional 30 minutes. Mice then received an i.p. injection of vehicle or equieffective doses of naltrexone (1 mg/kg), naloxone (10 mg/kg) or 6ß-naltrexol (10 mg/kg) and placed back into the chambers for an additional 60 minutes.
Physical Dependence Studies. Mice received acute or chronic exposure to morphine using a variety of protocols in an effort to produce increasingly severe levels of physical dependence.
These protocols are summarized in Table 1 . For the pellet implantation, mice were lightly anesthetized with ether and a small opening was cut into the back (scapular region) using surgical scissors. A single morphine (25 or 75 mg) or placebo pellet was inserted s.c. towards the lumbar region of the mouse and the wound was closed with two wound clips. The ability of each test compound to precipitate opioid withdrawal was assessed by administering i.p. doses at various times after the last morphine injection (or at 72 hr in the case of the morphine pellets).
Immediately after the injection, mice were placed into a clear Plexiglas cylinder with a filter paper bottom. Mice were videotaped for 20 minutes and the tapes analyzed by a trained observer who was blinded to all experimental treatments. Various measures were recorded for each mouse including vertical jumping, wet dog shakes, paw tremors, number of fecal boli, presence of diarrhea, and piloerection (Yano and Takemori, 1977; Sepúlveda et al., 1999) . Each nominal sign This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 16, 2005 as DOI: 10.1124 at ASPET Journals on November 13, 2017 jpet.aspetjournals.org Downloaded from was either present or absent and the number of paw tremors, body shakes, vertical jumps, and fecal boli for each animal was recorded.
In Vitro Competition Studies. Mice were made physically dependent to morphine using a 3-day escalating dosing regimen (Table 1) . Four hours after the last injection, the animals were sacrificed and the whole brain was rapidly removed and dissected, with tissues individually frozen in liquid nitrogen. Tissues were later thawed and tissue homogenates were incubated at 30°C for 30 minutes with concentrations of the test compounds (agonists, antagonists, inverse agonists) in the [ 35 S]GTPγS assay as previously described (Wang et al., 2004) in the presence of 10µM GDP. For the competition study, increasing concentrations of naloxone were added to the membrane homogenate with or without a fixed concentration of 6ß-naltrexol (10 µM).
In Vivo Competition Studies. Mice were made physically dependent to morphine using a 3-day escalating dosing regimen (Table 1) . Four hours after the last injection, mice were injected i.p.
with increasing doses of 6ß-naltrexol followed one minute later by an i.p. injection of a fixed dose of naloxone (10 mg/kg). Mice were then immediately placed into a Plexiglas observation cylinder and videotaped for 20 minutes. Vertical jumping was the primary index of withdrawal severity.
Statistical Analysis. Dose-response curves were analyzed as described above using FlashCalc software. Most of the other antinociceptive, locomotor and physical dependence data were analyzed using analysis of variance (ANOVA) followed by Games/Howell post-hoc analysis.
The nominal data were analyzed using chi-square. In all cases, significance was established at the p<0.05 level.
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Results
We have previously reported on the relative potencies of i.p. naloxone, naltrexone and 6ß-naltrexol to block the antinociceptive effects of an A 90 i.c.v. dose of morphine (Wang et al., 2001) . Table 2 We also tested for agonist activity in the 50°C tailflick and acetic acid writhing assays. Of the four compounds, only nalbuphine produced significant antinociceptive activity with ~30% MPE in the lower temperature tail-flick assay and ~90% suppression of writhing induced by 0.6% acetic acid (data not shown).
To further determine the potencies of each of the compounds to antagonize a CNS mediated effect of morphine, mice were pretreated with saline or increasing doses of each antagonist (i.p.) followed by a second injection of saline or a dose of morphine (30 mg/kg, s.c.). This dose of morphine strongly stimulates forward locomotion in ICR mice and produces a full antinociceptive effect in the 55°C tail-flick assay. Complete dose-response curves for all four antagonists were run, with the naltrexone, naloxone and 6ß-naltrexol graphs depicted in Figure 2 (panels A-C, respectively). Due to the relatively short duration of action of naloxone and naltrexone, a time window from 20-50 minutes post antagonist/morphine injections was chosen for analysis of total distance traveled for each group. This represented a time period when both This article has not been copyedited and formatted. The final version may differ from this version. Figure 2D and Table 2, respectively. The rank order of potency of the compounds was naltrexone > naloxone =6ß-naltrexol > nalbuphine.
To determine if any of the test compounds produced changes in locomotor-activity, separate control groups were run for each antagonist. Mice were injected i.p. with saline or the highest dose of each antagonist tested in the previous experiment. Thirty minutes later, mice were placed into the locomotor chambers for a thirty-minute session. This protocol was used to take advantage of the higher levels of activity mice display when initially placed in a novel environment (i.e., it has greater sensitivity for detecting drug effects that may either decrease or increase levels of activity). The results of these experiments are depicted in Figure 3 In contrast to the effects of naltrexone and naloxone, 6ß-naltrexol and nalbuphine both precipitated significantly less jumping in the acute models of physical dependence at doses up to 100 mg/kg. In the chronic model of physical dependence, the two compounds precipitated significant jumping with 6ß-naltrexol able to elicit as many vertical jumps as naltrexone and naloxone at a dose of 30 mg/kg. If a half-maximal level of jumping is set at 90 jumps/20 minutes, then the doses of naltrexone, naloxone and 6ß-naltrexol required to elicit a 50% response are 0.09, 0.29 and 6.9 mg/kg, respectively. Nalbuphine also precipitated robust jumping in the chronic dependence model with a maximal number of jumps of approximately 64 at 30 mg/kg. A higher dose of 60 mg/kg resulted in significant mortality. In contrast, we did not observe any mortality with the highest doses of 6ß-naltrexol tested during the 20 min withdrawal session.
Additional experiments were performed to look at the effects of varying the level of opioid physical dependence on the severity of antagonist-precipitated withdrawal as indexed not only by vertical jumping but by other classic measures as well. We initially chose three dosing regimens that involved x3 daily injections of s.c. morphine, with the rationale being that injectable morphine would offer more consistent tissue levels of drug when the precipitation of withdrawal was performed 4 hrs after the last injection of morphine. Pilot studies indicated that prolonging the duration of exposure from 3 to 6 days without further escalation of dose resulted in less physical dependence than with the 3 day regimen. We therefore chose to use a 72 hr s.c.
implantation of a 25 mg pellet of morphine for the highest level of physical dependence. This regimen resulted in less mortality during the 72 hr induction phase compared to a 75 mg pellet, while inducing a greater level of physical dependence versus the three-day escalating dose regimen.
As expected, there was a correlation between the level of physical dependence and the number of vertical jumps precipitated by a fixed dose of each antagonist. A 3x2 ANOVA indicated significant main effects for both morphine exposure (mild, moderate and severe) and drug (naltrexone and 6ß-naltrexol), F(2,68)=6.14, p<0.01 an F(1,68)=8.35, p<0.01, respectively.
The interaction between the two variables approached criteria for statistical significance, F(2,68)=2.94, p=0.06. With the mild dosing regimen, a comparison of the naltrexone and 6ß-naltrexol groups yielded a t(18)=1.37, p=0.19. At the two greater exposure levels, 6ß-naltrexol precipitated significantly less jumping behavior compared to naltrexone (p's <0.01).
Similar results were observed with the paw tremor measure ( Figure 5B ), though the data indicate that there was a ceiling effect with this measure (i.e., the moderate and severe dependence regimens resulted in roughly similar number of paw tremors within each particular treatment group). The ANOVA yielded an F(2,68)=3.4, p<0.05 and an F(1,68)=5.48, p<0.05, for the factors of treatment and drug. The only significant difference between the naltrexone and 6ß-naltrexol groups occurred at the severe level of morphine exposure, t(32)=2.11, p<0.04. For the This article has not been copyedited and formatted. The final version may differ from this version. "wet-dog" shakes ( Figure 5C ), the ANOVA yielded an F(2,68)=5.91, p<0.01 and F(1,68)=0.01, p=0.93 for the factors of treatment and drug. Post-hoc analysis indicated that the moderate and severe levels of morphine exposure resulted in greater numbers of antagonist-precipitated "wetdog" shakes compared to the mild exposure group with no differences observed between 6ß-naltrexol and naltrexone. The interaction between the two variables did not meet criteria for significance, F(2,68)=1.48, p=0.23.
As a crude index of gastrointestinal activity, the number of fecal boli was video recorded immediately after the withdrawal session ( Figure 5D ). Quantification of the number of feces indicated a similar pattern to the jumping and paw tremor graphs in that (a) there is a correlation between the number of fecal boli and the level of morphine exposure, and (b) the 6ß-naltrexol groups had fewer feces present compared to the naltrexone group at a given level of morphine exposure. The ANOVA had F values for the main factors of treatment and drug of 25.58 and 8.74, p's<0.001 and 0.005, respectively. Post-hoc analysis indicated significantly less feces at the moderate and severe morphine exposure levels (p's = 0.01).
With further reference to the measures of gastrointestinal activity, diarrhea was observed in some of the groups. This made the quantification of the fecal boli more difficult, with a best estimate made by an observer blinded to the experimental treatments for loose stools, with attention paid to the amount of material, its consistency and its location relative to other fecal output. The percent of animals having diarrhea (watery feces that soaked into the filter paper or smears) was also recorded. For the 6ß-naltrexol group, the % of animals having diarrhea was 0, 0 and 41% (7/17) for the mild, moderate and severe dependence paradigms. For the naltrexone groups it was 40 (4/10), 30 (3/10) and 65% (11/17), respectively. This article has not been copyedited and formatted. The final version may differ from this version. The next set of experiments addressed the question of whether 6ß-naltrexol was able to enter the central nervous system to reverse a CNS effect of morphine within the twenty minute time period that was used for the dependence assays. We used a modified locomotor procedure to assess this with one-minute intervals rather than the five-minute bins ( Figure 6 ). All experimental groups had a similar pattern of habituation (0-30 minutes) and induction of the morphine effect (30-60 minutes). Mice receiving a saline injection at 60 minutes continued to display a strong morphine locomotor effect for the remainder of the session (60-120 minutes). In contrast, all four test compounds (equieffective doses in antagonizing morphine antinociception) quickly reversed the locomotor stimulating effects of morphine, reducing the morphine effect by >90% within 10 minutes (Figure 6 ). When the groups were expressed as a percent of their 60 min pre-injection activity, the initial reductions in distance traveled were approximately linear (correlation values were 0.90, 0.82, 0.97 and 0.90 for naltrexone, naloxone, 6ß-naltrexol and nalbuphine). The calculated time to 50% reduction of the morphine effect (and 95% confidence limits) were 3.1 (2.6-3.7), 3.26 (3.0-3.6), 5.1 (4.5-5.9) and 5.2 (4.2-6.5) minutes, respectively.
From the locomotor studies depicted in Figure 2 , it appeared that the antagonist effects of naloxone and naltrexone began to wear off within the 90 minutes after the injection of the drugs.
The 55°C tail-flick assay was used to further assess the duration of action of these compounds antinociception, indicating that the effects of the antagonist were of relatively short duration. In contrast, the duration of action of 6ß-naltrexol was at least 6 hours, with a return to control levels between 12-24 hours.
Further experiments tested the hypothesis that neutral antagonists can competitively antagonize the effects of inverse agonists. We tested naloxone, 7-benzylidenenaltrexone (BNTX), and 6ß-naltrexol in brain and spinal cord tissue harvested from saline or morphine treated mice using the [ enhanced and the inverse agonist effects of naloxone emerged. Importantly, the magnitude of the agonist effect of morphine (~+15%) was similar to the magnitude of the inverse agonist effects of naloxone (~-10%). The trend towards blunted agonist effects and enhanced inverse agonist effects further increased with a 75 mg morphine pellet treatment for 3 days; data not shown). Therefore, in the morphine-dependent state, agonist and inverse agonist effects of morphine and naloxone, respectively, are of similar magnitude.
Given the importance of opioid receptors in the locus coeruleus and periaqueductal gray matter in mediating opioid withdrawal (Maldonado et al., 1992b ) and the results summarized in Table 3 , we chose to use brainstem/midbrain tissue for 6ß-naltrexol competition studies.
Moreover, the brainstem/midbrain homogenates were primarily sensitive to mu opioid receptor agonists, but not to delta and kappa selective opioid agonists, so that any contribution from opioid receptors other than the mu opioid receptor is minimized. In control tissues, naloxone produced a small increase in [ 35 S]-GTPγS binding at high nM and low µM concentrations ( Figure 9A ). In contrast, naloxone acted as an inverse agonist in tissues harvested from morphine treated mice ( Figure 9A ), as shown previously. 6ß-Naltrexol did not produce significant effects on [ 35 S]-GTPγS binding in brainstem tissues harvested from either saline or morphine treated mice ( Figure 9B ). Additional concentration-response curves were run with naloxone using brainstem/midbrain tissue from morphine pretreated mice in the absence or presence of 10µM 6ß-naltrexol ( Figure 9C ). The co-incubation of 6ß-naltrexol produced a large rightward shift in the naloxone concentration-response curve (EC 50 values for control and 6ß-naltrexol curves of 190 ± 40 nM and ~9,000 nM, respectively). In similar studies, the same concentration of 6ß-naltrexol was also able to produce a ~24-fold rightward shift in the concentration response curve for BNTX (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. injection of saline or increasing doses of 6ß-naltrexol. The co-injection of 6ß-naltrexol doserelatedly decreased naloxone-induced withdrawal jumping ( Figure 8D ), F(4,45)=3.85, p<0.01.
The 10 and 30 mg/kg doses of 6ß-naltrexol were significantly different from the naloxone control (p's < 0.01 and 0.001, respectively).
Discussion
The current study extended our characterization of 6ß-naltrexol by comparing its pharmacology to nalbuphine (partial agonist) and naloxone and naltrexone (inverse agonists) (Traynor et al., 2002; Walker et al., 2004) . We established the potency of the compounds to block acute effects of morphine (antinociception and locomotor-activity). Naltrexone was ~3-10-fold more potent than naloxone and 6ß-naltrexol. Nalbuphine had roughly similar antagonist potencies in the antinociceptive assays but was significantly less potent in blocking locomotoractivity. None of the antagonists stimulated activity by themselves when tested at the highest dosing levels. We did observe mild stimulation following a 10 mg/kg dose of nalbuphine (125% above saline controls versus >350% w/morphine). This could have accounted for the relatively low potency in this assay. None of the test compounds produced antinociception in the 55°C tailflick assay. Agonist effects of nalbuphine were apparent in the 50°C tail-flick and acetic acid writhing assays. 6ß-Naltrexol did not produce observable agonist effects, clearly distinguishing it from nalbuphine.
In the dependence assays, vertical jumping was used as the primary withdrawal measure as it is one of the most reliable measures of withdrawal severity, correlating with dose and duration of opioid exposure and the dose of naloxone injected (Blasig et al., 1973; Buccafusco et al., 1984; Kest et al., 2002) . In the acute dependence assay, naloxone and naltrexone precipitated significant withdrawal jumping at doses that blocked acute effects of morphine. Higher doses (30 and 60 mg/kg) elicited further increases in withdrawal jumping, with naltrexone producing behaviors that may interfere with jumping behavior. These behaviors were not observed in opioid naïve animals. In contrast, the neutral antagonist 6ß-naltrexol and the partial agonist This article has not been copyedited and formatted. The final version may differ from this version. nalbuphine both failed to precipitate withdrawal jumping at 10 mg/kg, doses that block morphine antinociception and locomotor-activity.
In the chronic dependence model, naltrexone and naloxone precipitated jumping at doses 30-60 times lower than in the acute dependence model, consistent with previous results (Way et al. 1969 ). 6ß-Naltrexol was 25-and 77-fold less potent than naloxone and naltrexone in precipitating withdrawal. This is in contrast to its antagonist potencies against morphine antinociception (equipotent to naloxone and 5-10-fold less potent than naltrexone). The significantly lower potency of 6ß-naltrexol in eliciting withdrawal is consistent with the hypothesis that suppression of basal mu opioid receptor signaling by an inverse agonist contributes to withdrawal. At very high doses 6ß-naltrexol was able to precipitate as severe a withdrawal as that of naloxone and naltrexone, even though mu opioid receptor sites are presumably saturated at lower doses. 6ß-Naltrexol may act as a competitive antagonist in displacing morphine from mu opioid receptors, whereas naloxone acts noncompetitively as an inverse agonist on basal mu opioid receptor activity. Alternatively, 6ß-naltrexol could have acted with low potency at a mu opioid receptor conformation specifically involved in dependence, to which naloxone has high affinity. Additional studies are needed to resolve these questions.
With respect to withdrawal, nalbuphine resembles 6ß-naltrexol. Opioid agonists with low efficacy can precipitate withdrawal in patients that are physically dependent (Preston et al., 1989; Preston et al., 1990 ). This presumably occurs by displacing morphine from opioid receptors.
Moreover, dependent subjects go through a protracted withdrawal syndrome as agonist drug levels decrease over time, indicating that there are compensatory systems that become uninhibited as drug effects wear off (Gonzalez et al., 2004) . We propose that the intrinsic inverse We addressed the question of how varying the level of physical dependence affects antagonist-induced withdrawal. We used moderate doses of naltrexone and 6ß-naltrexol to avoid ceiling or basement effects. Naltrexone elicited an increased severity of withdrawal with each of the measures, whereas an equivalent dose of 6ß-naltrexol produced less severe withdrawal in most measures. This was particularly pronounced with increasing degree of dependence for vertical jumping (robust measure of dependence). The number of fecal pellets (crude measure of gastrointestinal motility/overactivity) and the incidence of diarrhea showed similar patterns.
A ceiling effect may have been reached with the paw tremor measure, as there was little further increase in the number of tremors from the moderate to severe exposure levels. At moderate levels of morphine exposure, 6ß-naltrexol precipitated more wet-dog shakes than naltrexone, but this did not meet criteria for statistical significance. This behavior has been labeled a recessive sign of morphine withdrawal, being predominant when dependence is at a moderate level, and decreasing during more severe withdrawal when dominant signs (jumping) predominate (Blasig et al., 1973 , Valverde et al., 1992 . This is consistent with 6ß-naltrexol eliciting less severe withdrawal.
We have previously reported on blood and brain levels of naltrexone and 6ß-naltrexol following systemic injection into mice (Wang et al., 2004) . In vivo studies addressing functional pharmacokinetics provide additional data on the CNS penetration and duration of action of 6ß-naltrexol. Naloxone and naltrexone are relatively short acting antagonists in rodents (Berkowitz et al., 1975) . In contrast, 6ß-naltrexol has a much longer duration of action. The reversal of morphine-induced locomotor-activity indicated that all four compounds quickly act to block This article has not been copyedited and formatted. The final version may differ from this version. CNS effects of morphine. It is unlikely that these actions are due to non-specific effects, as none of the compounds significantly altered baseline levels of activity. 6ß-naltrexol (10 mg/kg i.p.)
can quickly reverse the respiratory depressant effects of morphine (200 mg/kg). These rescue doses work within one minute to prevent lethality. Furthermore, in mice receiving a 25 mg pellet of morphine, the time to first jump in mice that expressed this behavior was not significantly different between the four compounds tested. Collectively, the data indicate that the observed differences in withdrawal severity between inverse agonists, "neutral" antagonists, and partial agonist, are not due to differences in penetration rates/onset of antagonist actions.
A neutral antagonist should block the effects of an inverse agonist. We tested this hypothesis by measuring interactions between naloxone and 6ß-naltrexol in membrane homogenates.
Brainstem/midbrain tissue harvested from morphine treated mice yielded readily detectable inverse agonist effects on GTPγS binding for naloxone and BNTX. Direct comparison between the magnitude of agonist and inverse agonist effects, under identical conditions including relatively low GDP levels, indicated that the inverse effects are of the same order of magnitude as agonists effects in the morphine-dependent state. Owing to the difficulty in measuring basal levels of GTPγS binding in heterogeneous brain tissues, the maximal effects we have observed are ~10% for naloxone and ~20% for BNTX. This compares favorably to inverse agonist effects measured in cerebral membrane homogenate for the histamine H3 receptor (maximally 5%), where inverse agonists are clearly distinct from a neutral antagonist (Gbahou et al., 2003; Rouleau et al., 2002) . We conclude that the observed inverse agonist effects at mu opioid receptors in brain tissue are potentially significant, and reliably detectable above background noise.
This article has not been copyedited and formatted. The final version may differ from this version. The magnitude of the inverse effect on GPCR coupling does not necessarily reflect the magnitude of any physiological/pharmacological response, as the mu opioid receptor appears to be differentially regulated and coupled in different tissues (Table 3) This article has not been copyedited and formatted. The final version may differ from this version. 
